Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume – What’s Next?

Pharvaris (NASDAQ:PHVS) saw unusually-strong trading volume on Wednesday . Approximately 37,985 shares were traded during mid-day trading, a decline of 19% from the previous session’s volume of 47,045 shares.The stock last traded at $17.41 and had previously closed at $17.85.

Analyst Upgrades and Downgrades

Separately, JMP Securities increased their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Up 1.9 %

The company has a market cap of $933.90 million, a PE ratio of -6.38 and a beta of -3.08. The firm has a 50 day simple moving average of $18.42 and a 200-day simple moving average of $19.35.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Sphera Funds Management LTD. increased its position in shares of Pharvaris by 8.9% during the third quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock worth $8,136,000 after purchasing an additional 36,027 shares in the last quarter. Patient Square Capital LP purchased a new position in shares of Pharvaris in the third quarter worth about $4,488,000. State Street Corp acquired a new position in Pharvaris in the 3rd quarter worth approximately $1,000,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Pharvaris during the 3rd quarter worth approximately $906,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after acquiring an additional 5,753 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.